Experimental CAR t therapy targets two cancers at once
NCT ID NCT04162353
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This early-stage trial is testing a new type of immune cell therapy called BCMA-CD19 cCAR T cells in 12 patients with multiple myeloma or plasmacytoid lymphoma that has come back or not responded to standard treatments. The therapy uses a patient's own modified immune cells to attack cancer cells. The main goal is to see if the treatment is safe and tolerable.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BCMA-CD19 cCAR T cells
- What this could lead to
- If this works, it could point toward a new treatment option for patients with multiple myeloma or plasmacytoid lymphoma who have run out of standard therapies.
- What could go wrong
- This is a very early Phase 1 trial with only 12 participants, so it is primarily checking safety, not effectiveness. The treatment may cause serious side effects or not work at all.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA IN RELAPSE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chengdu Military General Hospital
RECRUITINGChengdu, Sichuan, China
-
Peking University Shenzhen Hospital, China
RECRUITINGShenzhen, Guangdong, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered donor cells could outsmart relapsed myeloma
- Can a Triple-Drug cocktail tame resistant myeloma?
- Can a single gene therapy turn the body into a Cancer-Fighting factory?
- Can a One-Two drug punch beat back Hard-to-Treat myeloma?
- CAR-T breakthroughs come with infection risks – new study aims to decode them
- Engineered immune cells take on incurable blood cancer